Well, it depends; 75% of our investment is in sub-Saharan Africa, because this is where the highest burdens are and the lowest economic capacities can be found. We have seen progress across the three diseases and across the regions, but perhaps I would flag that the disease that was mostly left behind before COVID, and that most suffered from COVID as well, is tuberculosis. The innovations have not been as active as they could have been. The treatments are still the old treatments, etc. Innovation has not been sufficient in that space. There are a lot of challenges in the tuberculosis space. We saw that in the context of COVID as well. The two have been very much combined and have created more vulnerability for the countries with a high prevalence of tuberculosis, such as India, for example.
I wouldn't say that a region is doing particularly better than another one, but we do have perhaps more entrenched challenges in the tuberculosis space that we need to tackle.